Polymorphisms of ERCC1, XRCC1 and its association with survival to platin-based chemotherapy in advanced non-small cell lung cancer
Hong-yan CHENG,Bao-an CHEN,Xin-chen SUN,Yu-xia DENG,Ning SUN,Yuan-dong CAO
DOI: https://doi.org/10.3969/j.issn.1671-6264.2011.05.013
2011-01-01
Abstract:Objective: To investigate the relationship between genetic polymorphisms of ERCC1,XRCC1 and survival of patients with advanced non-small cell lung cancer(NSCLC) treated with platinum based chemotherapy.Methods: A total of 120 patients with advanced NSCLC were routinely treated by cisplatin or carboplatin based chemotherapy.The polymorphic genotypes were analyzed by gene-chip method using DNA samples isolated from peripheral blood before treatment.Besides,10% samples were extracted randomly for sequencing to test the accuracy of this method.To explored the association between SNP of ERCC1(118),XRCC1(399) and prognosis to platinum-based chemotherapy in advanced NSCLC patients.Results: Homozygous wild type,heterozygote type and homozygous mutant type yielded green,yellow and red fluorescence,respectively.The results were according to gene sequencing.Median follow-up period was 11 months.MST,1-year survival,2-year survival and 3-year survival rates of patients with the ERCC1(118)C/C genotype,C/T+T/T genotype were 10.9 months,35.9%,6.3% and 1.6% vs 13.5 months,59.5%,19.0% and 14.3% respectively,with significant difference(P<0.05).MST and 1-year survival,2-year survival and 3-year survival rates of patients with the XRCC1(399) G/G genotype and G/A+A/A genotype were 15.2 months and 59.1%,15.9%,6.8% vs 11.1 months,35.5%,8.1%,6.5% respectively,with significant difference(P<0.05).Conclusion: Polymorphisms of ERCC1,XRCC1 might be associated with overall survival period in patients with advanced NSCLC after treatment with platin-based chemotherapy,which might be the predictive markers for overall survival.